image: Phage Therapy and the Medicine of Tomorrow: Scientists Meet in Valencia to Define the Path to Clinical Integration
Credit: Targeting Phage Therapy 2026
Phage Therapy and the Medicine of Tomorrow: Scientists Meet in Valencia to Define the Path to Clinical Integration
Valencia, Spain. June 9–10, 2026
Researchers, clinicians, and biotechnology innovators from around the world will gather in Valencia, Spain, for Targeting Phage Therapy 2026, an international scientific meeting dedicated to advancing bacteriophage based strategies to combat antimicrobial resistance and difficult to treat bacterial infections.
Phage therapy using viruses that specifically infect and eliminate bacteria has re emerged as a promising approach as the effectiveness of antibiotics continues to decline worldwide. Despite growing scientific interest and encouraging clinical cases, translating phage therapy from experimental use into standardized and predictable clinical practice remains a major scientific and regulatory challenge.
The meeting will explore how bacteriophages may contribute to what many researchers describe as the medicine of tomorrow, a more precise and adaptive approach to infectious disease treatment in which targeted biological agents complement conventional antimicrobial strategies.
Over two days, the conference will bring together experts in microbiology, infectious diseases, biotechnology, clinical research, and regulatory science to address the scientific and translational barriers that still limit broader clinical deployment of phage therapy.
Key questions shaping the future of the field will be addressed, including:
- How can phage therapy demonstrate consistent clinical efficacy in complex infections?
- What level of manufacturing and quality standardization is required for regulatory approval?
- How can phages be integrated responsibly within existing antimicrobial stewardship frameworks?
- What evidence is necessary to transition from compassionate use to structured clinical protocols?
Sessions will examine advances in phage host interactions, biofilm associated infections, scalable phage production technologies, regulatory frameworks, and clinical translation pathways.
The meeting is designed as a discussion driven forum aimed at strengthening collaboration between academic laboratories, hospitals, and biotechnology companies working on next generation antimicrobial solutions.
“Phage therapy is moving from a historical concept to a scientifically structured medical strategy,” said Sandra Sevilla, President of Phage Therapy 2026. “Our goal is to create a platform where scientists and clinicians can openly discuss remaining bottlenecks and define the roadmap toward predictable and regulated therapeutic use.”
By emphasizing interdisciplinary dialogue and translational science, Targeting Phage Therapy 2026 aims to clarify the scientific, technological, and regulatory pathways required to integrate bacteriophage based therapies into modern medicine.
The meeting will take place June 9–10, 2026, in Valencia, Spain, and is expected to attract participants from leading research institutions, hospitals, and biotechnology companies worldwide.
More information is available at https://phagetherapy-site.com/
Global Health Context
Antimicrobial resistance is widely recognized as one of the most pressing global health challenges of the 21st century. Drug resistant bacterial infections are increasing worldwide, reducing the effectiveness of many existing antibiotics and complicating the treatment of common infections. In this context, bacteriophages viruses that naturally infect bacteria are receiving renewed scientific attention as potential precision antimicrobials. Unlike broad spectrum antibiotics, phages can specifically target pathogenic bacteria while leaving beneficial microbial communities largely unaffected. Researchers increasingly view phage therapy as a complementary strategy that could help address infections that are difficult or impossible to treat with conventional antibiotics.